哪种结核病吃氯法齐明？

Clofazimine indications

People with multidrug-resistant tuberculosis need treatment. Clofazimine is the main drug used to treat leprosy, and in recent years it has proven to be an important option for the treatment of multidrug-resistant tuberculosis.

Clofazimine is effective against the tuberculosis bacteria that cause tuberculosis. It is a representative drug for the new use of old drugs in the field of treating multi-drug-resistant tuberculosis. It can effectively increase the sputum negative conversion rate, lesion absorption rate and cavity shrinkage rate of multi-drug-resistant tuberculosis without increasing the incidence of adverse drug reactions. It is an important drug recommended by the World Health Organization for the treatment of multi-drug-resistant tuberculosis.

multidrug-resistant tuberculosis

According to a 2012 World Health Organization report, there were approximately 630,000 cases of multidrug-resistant tuberculosis worldwide in 2011. The multidrug resistance rate of Mycobacterium tuberculosis in my country is 8.32%, of which the multidrug resistance rate of strains in newly treated smear-positive patients is 5.71%, which is higher than the world average. There are approximately 120,000 new MDR-TB patients every year.

Multidrug-resistant tuberculosis is an extremely complex type of tuberculosis. It refers to the tuberculosis bacteria (the pathogenic bacteria that cause tuberculosis) in tuberculosis patients that are resistant to the two anti-tuberculosis drugs "isoniazid" and "rifampicin". The main cause of multidrug-resistant tuberculosis is inappropriate or incorrect use of anti-tuberculosis drugs, which increases the risk of the spread of drug-resistant strains.

Clofazimine for the treatment of multidrug-resistant tuberculosis

Clofazimine has no cross-resistance with existing anti-tuberculosis drugs and has a good effect against drug-resistant tuberculosis. Clofazimine-containing regimens are safer and more effective in treating multi-drug-resistant and extensively drug-resistant tuberculosis.

The clofazimine combination regimen for the treatment of multidrug-resistant tuberculosis has relatively strong advantages in the intensive phase, which can significantly improve the efficacy and alleviate the economic burden and disease distress caused by the disease.

Clofazimine may cause nausea, vomiting, diarrhea and other gastrointestinal disturbances during use. However, there is no need to stop taking the medication, just symptomatic treatment.

In short, the clofazimine combination regimen for the treatment of multidrug-resistant tuberculosis can significantly improve the patient's positive to negative conversion rate and smear positive to negative conversion rate during the intensive phase of treatment. It has good clinical efficacy, no serious adverse reactions, and is highly safe.

References

[[1] Lei Jianping, Tu Guangrong. Analysis of the clinical efficacy of chlorfazimine-containing combination regimen in the treatment of multidrug-resistant tuberculosis [C]//"Chinese Journal of Anti-Tuberculosis" Editorial Board, "Journal of Tuberculosis and Lung Health" Editorial Board, Shantou Third People's Hospital. Compilation of materials from the symposium on progress in the diagnosis and treatment of drug-resistant tuberculosis and pulmonary infectious diseases. [Unknown publisher], 2013: 92-94.

Recommended related articles: